131 related articles for article (PubMed ID: 16258463)
1. Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions?
Baglin TP
Clin Adv Hematol Oncol; 2003 Nov; 1(11):656-7. PubMed ID: 16258463
[No Abstract] [Full Text] [Related]
2. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype.
Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U
Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471
[No Abstract] [Full Text] [Related]
3. PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics.
Owen RP; Altman RB; Klein TE
Hum Mutat; 2008 Apr; 29(4):456-60. PubMed ID: 18330919
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
[TBL] [Abstract][Full Text] [Related]
5. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
Ruud E; Holmstrøm H; Bergan S; Wesenberg F
Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
[TBL] [Abstract][Full Text] [Related]
6. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
[TBL] [Abstract][Full Text] [Related]
7. Overview of pharmacogenetics in anticoagulation therapy.
Hill CE; Duncan A
Clin Lab Med; 2008 Dec; 28(4):513-24. PubMed ID: 19059059
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
Takahashi H; Wilkinson GR; Padrini R; Echizen H
Clin Pharmacol Ther; 2004 May; 75(5):376-80. PubMed ID: 15116049
[No Abstract] [Full Text] [Related]
9. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin.
D'Ambrosio RL; D'Andrea G; Cappucci F; Chetta M; Di Perna P; Brancaccio V; Grandone E; Margaglione M
Haematologica; 2004 Dec; 89(12):1510-6. PubMed ID: 15590403
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacogenetics in practice].
Spigset O
Tidsskr Nor Laegeforen; 2008 Aug; 128(15):1679. PubMed ID: 18720559
[No Abstract] [Full Text] [Related]
11. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
[TBL] [Abstract][Full Text] [Related]
12. Use of pharmacogenetics to guide warfarin therapy.
Voora D; McLeod HL; Eby C; Gage BF
Drugs Today (Barc); 2004 Mar; 40(3):247-57. PubMed ID: 15148533
[TBL] [Abstract][Full Text] [Related]
13. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
Muszkat M; Bialer O; Blotnick S; Adar L; Xie HG; Ufer M; Cascorbi I; Caraco Y
Clin Ther; 2010 Feb; 32(2):347-56. PubMed ID: 20206792
[TBL] [Abstract][Full Text] [Related]
14. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
Yildirim H; Tamer L; Sucu N; Atik U
Med Princ Pract; 2008; 17(6):464-7. PubMed ID: 18836275
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics and warfarin therapy.
Ndegwa S
Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
[TBL] [Abstract][Full Text] [Related]
16. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics.
Lesko LJ
Clin Pharmacol Ther; 2008 Sep; 84(3):301-3. PubMed ID: 18714317
[No Abstract] [Full Text] [Related]
17. Clinical factors influencing the sensitivity to warfarin when restarted after surgery.
Schulman S; El Bouazzaoui B; Eikelboom JW; Zondag M
J Intern Med; 2008 Apr; 263(4):412-9. PubMed ID: 18205763
[TBL] [Abstract][Full Text] [Related]
18. [A 60-year-old man with heart failure, dry cough and elevated INR values].
Kamal Z; Nordstad MG; Molden E
Tidsskr Nor Laegeforen; 2008 Aug; 128(15):1677-9. PubMed ID: 18720558
[No Abstract] [Full Text] [Related]
19. [Association of polymorphisms of cytochrome P450 2C9 exon 4 and -65G>C with warfarin sensitivity].
Wang ZX; Huang L; Cai H; Men JL; Wei MX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Aug; 27(4):428-32. PubMed ID: 20677151
[TBL] [Abstract][Full Text] [Related]
20. A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy.
Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V
Thromb Haemost; 2006 Jan; 95(1):192-4. PubMed ID: 16543980
[No Abstract] [Full Text] [Related]
[Next] [New Search]
